Strategic Investment
We belong to a new breed of biotech investor that strongly believes in the concept of “smart money”. We combine our capital with our collaborative drug development team to deliver a unique investment formulation.
We belong to a new breed of biotech investor that strongly believes in the concept of “smart money”. We combine our capital with our collaborative drug development team to deliver a unique investment formulation.
KreaMedica Holdings Inc. invests in fast-growing biotechnology companies that develop innovative drugs or disruptive technologies. We focus on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit growth potential. Furthermore, we focus on the earlier phases of development, where most of the funding challenges exist.
Acesis Holdings Corporation and its wholly-owned subsidiary Acesis Biomed US, is an emerging, pre-phase 1 biotechnology company focused on men’s health developing novel, non-steroid treatments for low testosterone (T) levels in males known as T-deficiency or male hypogonadism and related co-morbidities
OrthoTreat revolutionizes the field of bone regeneration by harnessing physiological regulation to enhance the natural bone healing process. A distinctive approach synergises two FDA-approved Active Pharmaceutical Ingredients (APIs), with complementary biochemical mechanisms, to forge an innovative, efficient, and safe treatment pathway for bone-related conditions.